Q2 2025 Financial Performance - Total revenue increased to $15.3 million, compared to $8.0 million in Q2 2024[11] - Product gross margin improved significantly to 72% from 45% in Q2 2024[11] - Loss from operations decreased to ($12.9) million from ($22.7) million year-over-year[11] - Net loss per share improved to ($0.16) from ($0.32) year-over-year[11] Business Highlights - The company is experiencing growing momentum with ECO Synthesis, with 34 ongoing customer engagements[7] - Customers are bringing their most complex manufacturing challenges to Codexis, indicating strong demand for their solutions[10] - Chemo-enzymatic route (ligation) is becoming the new standard in siRNA manufacturing, benefiting the company's ligase business[10] Strategic Focus - The company is shifting emphasis to newer assets with longer runway and better economics[7] - The company is exploring the development of a Codexis-owned GMP facility[10] - The company continues to carefully manage burn rate and reiterates 2025 guidance range[13]

Financial Performance - Q2 2025 revenue increased by 56% to $7476000 compared to $4777000 in Q2 2024[6] - Net income for Q2 2025 was $225000, a 109% increase compared to a net loss of $2553000 in Q2 2024[6] - Adjusted EBITDA for Q2 2025 was $591000, a 656% increase compared to $78000 in Q2 2024[6] - For the first six months of 2025, revenue increased by 51% to $14532000 compared to $9654000 in the same period of 2024[6] - Net loss for the first six months of 2025 was $901000, a 76% decrease compared to a net loss of $3766000 in the same period of 2024[6] - Adjusted EBITDA for the first six months of 2025 was $540000, a 196% increase compared to $183000 in the same period of 2024[6] Growth Drivers - The Kyber acquisition contributed $1900000 to revenue growth in Q2 2025 and $3600000 year-to-date[11] - The Kyber acquisition accounted for approximately 39% of the Q2 revenue increase[11] - Internal growth accounted for approximately 17% of the Q2 revenue increase and 13% year-to-date[11] Outlook - The company expects full year 2025 revenue to be between $28000000 and $30000000, representing a 39% to 49% increase over 2024 revenue of $20200000[25] - The company expects adjusted EBITDA for full year 2025 to be between ($1000000) and $1000000[25]

Q4'FY25 Earnings Call Supplemental Presentation August 13, 2025 Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation relate, but are not limited, to: expectations regarding adjusted EBITDA and revenue; our ability to execute on our ...

Product & Technology - Hyperfine launched the next-generation Swoop system with Optive AI software in mid-2025, which is the first FDA-cleared, AI-powered portable MR brain imaging system[4,74] - The Swoop system is designed to improve brain health globally by expanding brain MR imaging to multiple healthcare settings[4,10] - The new Swoop system powered by Optive AI software brings image quality closer to conventional 1.5T MRI[40,75] Market Opportunity & Growth Strategy - The company estimates a total addressable market (TAM) exceeding $6 billion, potentially expanding to over $16 billion with new sites of care[4,19] - Hyperfine has an installed base of over 180 Swoop systems globally as of June 2025[60] - The company's growth strategy focuses on expanding to new sites of care, including emergency departments, clinics, and neurology offices, as well as geographic expansion[74] Financial Performance - Hyperfine anticipates revenue between $27 million and $29 million for FY25, with gross margins between 47% and 50%[71] - The company projects a 10-20% year-over-year revenue growth for 2025[68] - Hyperfine had $25.4 million in cash and cash equivalents as of June 30, 2025, with a cash runway expected to last until the end of 2026[71]

A Regenerative Medicine Company Cellular therapies for life-threatening and chronic aging-related conditions Investor Presentation Nasdaq (LGVN) │ August 2025 Forward Looking Statements Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management's current expectations, assumptions, and estimates of future operations, performance and economic ...

Safe Harbor Statement Corporate Overview August - 2025 (All figures in USD) NASDAQ : ELVA TSX : ELVA Forward-looking statements: This presentation contains forward-looking statements and forward looking information (collectively, "forward-looking statements"), including statements that relate to, among other things, the size of the Company's addressable market and target verticals and applications, margin performance capabilities of new target operating segments, future operating jurisdictions including pla ...

Pipeline and Milestones - Alumis expects topline data from Phase 3 ONWARD trials for envudeucitinib in moderate-to-severe plaque psoriasis in early 1Q 2026[11] - Alumis anticipates topline data from Phase 2b LUMUS trial in systemic lupus erythematosus in 3Q 2026[11] - Alumis plans to initiate a Phase 2 clinical trial for A-005 in multiple sclerosis in 1H 2026[11] - Alumis is evaluating the development program for lonigutamab in thyroid eye disease[12] - Alumis expects Phase 1 data for its next program in 2026[12] Financial Position - Alumis had $486.3 million in cash as of June 30, 2025, providing runway into 2027[11] Envudeucitinib (TYK2 Inhibitor) - Envudeucitinib demonstrated a 15-20% increase in clinical response (PASI) with maximal target inhibition[23] - In the STRIDE trial, Envudeucitinib 40 mg BID showed a 64.1% PASI-75 response at Week 12[39] - Approximately 92% of diagnosed psoriasis patients are not treated with a biologic therapy, representing a market opportunity for Envudeucitinib[35] - Alumis is receiving $40 million near-term for Japan, <5% of Worldwide Psoriasis Market (estimated at $600M in 2024)[69] A-005 (CNS-Penetrant TYK2 Inhibitor) - A-005 achieves a CSF:Plasma (free drug) ratio of approximately 1:1, indicating full CNS penetration[75]

Company Overview - Dyadic is a bioprocessing platform company transitioning from R&D to commercial revenue generation[4, 10, 24] - The company has two validated platforms, C1 and Dapibus, targeting life sciences, food/nutrition, and bio-industrial markets[4, 24] - Dyadic's market capitalization is $3009 million as of July 21, 2025, with approximately $74 million in cash and investment-grade securities as of March 31, 2025[62] Market Opportunity - The company is targeting a $25 billion+ market opportunity across key segments[7, 62] - The recombinant food & nutrition market is estimated at ~$11 billion in 2025[16, 31] - The cell culture media market is estimated at ~$5 billion in 2025, while the molecular biology reagents market is estimated at ~$2 billion in 2025[25, 27] - The recombinant bio-industrial enzymes market is estimated at ~$6 billion in 2025[16, 36] Commercial Strategy - Dyadic is focused on non-therapeutic applications for near-term revenue generation[4, 20, 62] - The company utilizes three revenue pathways: strain licensing, strategic partnerships, and direct product sales[42] - Initial revenue streams are active, with multiple non-therapeutic protein products expected to launch over the next 12-36 months[7, 24]

Pipeline and Programs - Tenaya Therapeutics has 3 clinical-stage programs focused on heart disease[9] - TN-201, a gene therapy for MYBPC3-associated HCM, is in Phase 1b/2 clinical trials with data readouts expected in Q4 2025[10, 12] - TN-401, a gene therapy for PKP2-associated ARVC, is in Phase 1b clinical trials with initial data including safety and biopsy results expected in 2025[10, 94] - TN-301, a small molecule HDAC6 inhibitor for HFpEF, has completed Phase 1 trials and is seeking a partner for further development[10, 99, 104] TN-201 for MYBPC3-associated HCM - MYBPC3-associated HCM affects an estimated 120,000 people in the U S alone[22] - Interim Cohort 1 data for TN-201 showed the therapy was well-tolerated at 3E13 vg/kg dose, with no cardiotoxicities and manageable liver enzyme elevations[17, 40] - All three patients in Cohort 1 improved from NYHA class II/III to NYHA class I, and elevated troponin levels dropped by 60% in two patients into normal ranges[19] - TN-201 DNA in cardiac biopsy surpassed preclinical efficacy threshold and compares favorably to peer, with long-term stability achieved[42] - TN-201 RNA expression increased by as much as 13-fold from week 8 to Week 52[46] TN-401 for PKP2-associated ARVC - PKP2-associated ARVC is estimated to affect over 70,000 people in the U S [75] - Preclinical studies showed that a single 3E13 vg/kg dose of TN-401 in a KO mouse model reversed hallmarks of the disease and extended survival[91] - RIDGE natural history study shows that over 80% of ARVC patients continue to experience high PVC count despite standard of care treatments[87]

Financial Performance - Revenue reached $4.10 million in Q2 2025, a 113% year-over-year increase from $1.92 million in Q2 2024 [11] - Sequential QoQ revenue growth was 83% from Q1 2025 [1] - Gross profit was $1.08 million, resulting in a gross margin of 26.4%, up from 15.4% in Q2 last year [16] - Operating loss improved to $(3.62) million, compared to $(4.26) million in Q1 [20] - Operating cash usage improved to $(3.10) million in Q2 from $(3.84) million in Q1, a 19% reduction [23] Operational Highlights - Long-term debt declined to $2.09 million [34] - Inventory remained stable at $5.88 million [25, 28] - The company is targeting 200 units/day production by late Q3, compared to approximately 50 units/day at the start of 2025 [46] Growth Initiatives - The company estimates its B2B network can support over $21.5 million in annual repeatable revenue [41] - Over 50% of total unit volumes in Q2 came from direct online sales [42] - The company expects to increase to $40M ARR by year end [12] Future Outlook - The company reaffirms its full-year 2025 revenue target of $20 million+ [70] - The company believes AetherLux could have a meaningful impact on the company's 2026 balance sheet, supported by its position in the $123B global market [62]